Effect of wine phenolics on cytokine-induced C-reactive protein expression

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1309-1317

  Kaur, G ^a   Rao, L V M ^a   Agrawal, A ^b   Pendurthi, Usha R ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Quercetin; Resveratrol

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; QUERCETIN; RESVERATROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MESSENGER RNA SYNTHESIS; NONHUMAN; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

C-REACTIVE PROTEIN; CELL LINE; CYTOKINES; GENE EXPRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; PHENOLS; QUERCETIN; RNA, MESSENGER; STILBENES; WINE;

EID: 34250160235     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02527.x     Document Type: Article

References (71)

1. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279: 48487-90.
2. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
4. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
5. Verma S, Szmitko PE, Yeh ET. C-reactive protein: Structure affects function. Circulation 2004; 109: 1914-7.
6. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113: 2128-34.
7. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113: 2135-50.
8. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-7.
9. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005; 2: 29-36.
10. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
11. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98: 531-5.
12. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.
13. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110: 579-87.
14. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, Diez J, Libby P, Paramo JA. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78.
15. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
16. Rimm EB, Giovannucci EL, Willet WC, Colditz GA, Aschrio A, Rosner B, Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991; 338: 464-8.
17. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer wine or spirits. BMJ 1996; 312: 731-7.
18. Szmitko PE, Verma S. Cardiology patient pages. Red wine and your heart. Circulation 2005; 111: E10-1.
19. Jackson R, Scragg R, Beaglehole R. Alcohol consumption and risk of coronary heart disease. BMJ 1991; 303: 211-6.
20. Renaud S, De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1993; 339: 1523-6.
21. Constant J. Alcohol, ischemic heart disease, and the French paradox. Coron Artery Dis 1997; 8: 645-59.
22. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substrances in red wine. Lancet 1993; 341: 454-7.
23. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993; 341: 1103-4.
24. Aviram M, Fuhrman B. Wine flavanoids protect aganist LDL oxidation and atherosclerosis. Ann N Y Acad Sci 2002; 957: 146-61.
25. Tsai S-H, Lin-Shiau S-Y, Lin J-K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br J Pharmacol 1999; 126: 673-80.
26. Bertelli AA, Baccalini R, Battaglia E, Falchi M, Ferrero ME. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 2001; 56: 613-6.
27. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, Ito K, Russell RE, Barnes PJ. Anti-inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287: L774-83.
28. Renaud SC, Beswick AD, Fehily AM, Sharp DS, Elwood PC. Alcohol and platelet aggregation: The Caerphilly Prospective Heart Disease Study. Am J Clin Nutr 1992; 55: 1012-7.
29. Bertelli AAE, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tiss Reac 1995; 17: 1-3.
30. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis implications for protection against coronary heart disease. Clin Chim Acta 1995; 235: 207-19.
31. Pendurthi UR, Williams JT, Rao LVM. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells. A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler Thromb Vasc Biol 1999; 19: 419-26.
32. Pendurthi UR, Rao LVM. Effect of wine phenolics and stilbene analogues on tissue factor expression in endothelial cells. Thromb Res 2002; 106: 205-11.
33. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
34. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
35. Levitan EB, Ridker PM, Manson JE, Stampfer MJ, Buring JE, Cook NR, Liu S. Association between consumption of beer, wine, and liquor and plasma concentration of high-sensitivity C-reactive protein in women aged 39 to 89 years. Am J Cardiol 2005; 96: 83-8.
36. Kushner I, Feldmann G. Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med 1978; 148: 466-77.
37. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991; 147: 1261-5.
38. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay JF, Brouillard R, Raul F. Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 2003; 107: 189-96.
39. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M. Synthesis and biological evaulation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003; 46: 3546-54.
40. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 2000; 165: 4592-7.
41. Soleas GJ, Diamandis EP, Goldberg DM. Wine as biological fluid: History, production, and role in disease prevention. J Clin Lab Anal 1997; 11: 287-313.
42. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnon UM, Albini A, Prosperi E, Vannini V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001; 276: 22586-94.
43. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 1995; 310: 143-8.
44. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunol 2003; 108: 539-47.
45. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
46. Westra J, Bijzet J, Doornbos-van der Meer B, van Rijswijk MH, Limburg PC. Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines. Ann Rheum Dis 2006; 65: 929-35.
47. Seimann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992; 43: 49-52.
48. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
49. Soleas G, Diamandis EP, Goldberg DM. The world of resveratrol. Adv Exp Med Biol 2001; 492: 159-82.
50. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005; 16: 449-66.
51. Hao HD, He LR. Mechanisms of cardiovascular protection by resveratrol. J Med Food 2004; 7: 290-8.
52. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A, Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004; 68: 1113-8.
53. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001; 3: 1041-64.
54. Seigneur M, Bonnet J, Dorian B. Effect of the consumption of alcohol, white wine, and red wine on platelet function and serum lipids. J Appli Cardiol 1990; 5: 215-22.
55. Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am Physiol Soc 1993; 363: H774-8.
56. Lekakis J, Rallidis LS, Andreadou I, Vamvakou G, Kazantzoglou G, Magiatis P, Skaltsounis AL, Kremastinos DT. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 596-600.
57. Zern TL, West KL, Fernandez ML. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr 2003; 133: 2268-72.
58. Di Santo A, Mezzetti A, Napoleone E, Di Tommaso R, Donati MB, de Gaetano G, Lorenzet R. Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J Thromb Haemost 2003; 1: 1089-95.
59. Rosado JA, Nunez AM, Lopez JJ, Pariente JA, Salido GM. Intracellular Ca2 + homeostasis and aggregation in platelets are impaired by ethanol through the generation of H2O2 and oxidation of sulphydryl groups. Arch Biochem Biophys 2006; 452: 9-16.
60. Olsen H, Osterud B. Effects of ethanol on human blood fibrinolysis and coagulation. Alcohol Alcohol Suppl 1987; 1: 591-4.
61. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol a natural product derived from grapes. Science 1997; 275: 218-20.
62. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J, Merillon JM. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003; 72: 2219-33.
63. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, Gescher AJ. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer 2004; 90: 736-44.
64. Chen G, Shan W, Wu Y, Ren L, Dong J, Ji Z. Synthesis and anti-inflammatory activity of resveratrol analogs. Chem Pharm Bull (Tokyo) 2005; 53: 1587-90.
65. Kaur G, Roberti M, Raul F, Pendurthi UR. Suppression of human monocyte tissue factor induction by red wine phenolics and synthetic derivatives of resveratrol. Thromb Res 2007; 119: 247-56.
66. Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochem 1996; 35: 9060-8.
67. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/ enhancer binding protein beta (C/EBP beta) and Rel p50. J Immunol 2001; 166: 2378-84.
68. Agrawal A, Samols D, Kushner I. Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol Immunol 2003; 40: 373-80.
69. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996; 271: 9503-9.
70. Voleti B, Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 2006; 43: 891-6.
71. Voleti B, Agrawal A. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol 2005; 175: 3386-90.